Redefining the role of long-acting phosphodiesterase inhibitor tadalafil in the treatment of diabetic erectile dysfunction

Current Diabetes Reviews

Volumn 4, Issue 1, 2008, Pages 24-30

  Bruzziches, Roberto ^a   Greco, Emanuela A ^a   Pili, Marcello ^a   Francomano, Davide ^a   Spera, Giovanni ^a   Aversa, Antonio ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Cardiovascular disease; Diabetes mellitus; Endothelial dysfunction; Once a day dosing; Phosphodiesterase type 5 inhibitors

Indexed keywords

ANDROGEN; DOXAZOSIN; ENDOTHELIN; LONG ACTING DRUG; PHOSPHODIESTERASE INHIBITOR; PLACEBO; RIFAMPICIN; SEX HORMONE; SILDENAFIL; TADALAFIL; TAMSULOSIN; TESTOSTERONE; VARDENAFIL;

ANDROGEN DEFICIENCY; BACKACHE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLOR VISION; DISEASE SEVERITY; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE TIME EFFECT RELATION; DRUG ALCOHOL INTERACTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ERECTILE DYSFUNCTION; EVENING DOSAGE; FOOD DRUG INTERACTION; HEARING LOSS; HEART INFARCTION; HUMAN; HYPOGONADISM; INSULIN DEPENDENT DIABETES MELLITUS; LIPID DIET; METABOLIC SYNDROME X; MORNING DOSAGE; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTIC NERVE DISEASE; PATHOGENESIS; POSTMARKETING SURVEILLANCE; PRIAPISM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QT PROLONGATION; REVIEW; RHINOPHARYNGITIS; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; STEM CELL; TESTOSTERONE BLOOD LEVEL; TINNITUS; TREATMENT DURATION; VERTIGO; VESTIBULAR DISORDER; VISUAL DISORDER;

CARBOLINES; DIABETES COMPLICATIONS; DRUG ADMINISTRATION SCHEDULE; ERECTILE DYSFUNCTION; HUMANS; MALE; PHOSPHODIESTERASE INHIBITORS; RETROSPECTIVE STUDIES; SAFETY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 38949107412     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339908783502389     Document Type: Review

References (69)

1. Andersson KE, Becher E, Hendry B, et al. Recommendations of the 1st International Consultation on Erectile Dysfunction. In Jardin A, Wagner G, Khoury S, Giuliano F, Padma-Nathan H, Rosen R, eds. Erectile disfunction. 1st International Consultation on Erectile Dysfunction - July 1-3, 1999, Paris. Plymouth: Plymbridge Distributors Ltd; 1999; 711-13.
2. Ayta IA, McKinlay JB, Krane RJ. The likely world wide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84: 50-6.
3. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA 1979; 241: 2035-2038.
4. Haffner SM, Lehto S, Ronnemaa T, Pyorala Y, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
5. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: A statement for health professionals from the American Heart Association. Circulation 1999; 100: 1134-1146.
6. Sairam K, Kulinskaya E, Boustead GB, Hanbury DC, Mcnicolas TA. Prevalence of undiagnosed diabetes mellitus in male erectile dysfimction. BJU Int 2001; 88: 68-71.
7. Fedele D, Bortolotti A, Coscelli C, et al. Erectile dysfunction in type I and type 2 diabetics in Italy. Int J Epidemiol 2000; 29: 524-31.
8. Panza JA, Quyyumi AA, Brush JE, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22-27.
9. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899.
10. Vitale C, Mercuro G, Cornoldi A, Fini M, Volterrani M, Rosano GM. Metformin improves endothelial function in patients with metabolic syndrome. J Intern Mod 2005; 258(3): 250-256.
11. Aversa A, Pili M, Fabbri A, Spera E, Spera G. Erectile dysfunction: expectations beyond phosphodiesterase type 5 inhibition. J Endocrinol Invest 2004; 27: 192-206.
12. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for the treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999; 281: 421-26.
13. Ceriello A, Assaloni R, Da Ros R, et al. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 2005; 111(19):2518-24.
14. Behr-Roussel D, Gorny D, Mevel K, et al. Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis. Eur Urol 2005; 47(1): 87-91.
15. Rosano GM, Aversa A, Vitale C, Fabbri A, Fini M, Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005; 47(2): 214-20; discussion 220-2.
16. Carson CC, Lue TF. Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int 2005; 96(3): 257-80.
17. Forgue ST, Patterson BE, Bedding AW, et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2006; 61(3): 280-8.
18. Patterson B, Bedding A, Jewell H, Payne C, Mitchell M. The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC351). Poster presented at: 4th Biennial Meeting of the European Society for Sexual and Impotence Research; Rome, Italy, September 30 to October 3, 2001.
19. Supuran CT, Mastrolorenzo A, Barbaro G, Scozzafava A. Phosphodiesterase 5 inhibitors - drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles. Curr Pharm Des 2006; 12(27): 3459-3467.
20. Barbaro G, Scozzafava A, Mastrolorenzo A, Supuran CT. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des 2005; 11: 1805-1843.
21. Carson CC, Lue TF. Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int 2005; 96: 257-80.
22. Cialis® (tadalafil) prescribing information. Lilly ICOS LLC; Indianapolis, Ind, and Bothell, Wash; 2003.
23. Sussman DO. Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors. J Am Osteopath Assoc 2004; 104 (3 Suppl 4): S11-5.
24. Kloner RA, Hutter AM, Emmick JT, Mitchell MI, Denne J, Jackson G. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 2003; 42 (10): 1855-60.
25. Kloner RA, Jackson G, Eminick JT, et al. A. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 2004; 172 (5 Pt 1): 1935-40.
26. Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005; 96: 313-321.
27. Montorsi F, Verheyden B, Meuleman E, et al. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol 2004; 45 (3): 339-44.
28. Rashid A. The efficacy and safety of PDE5 inhibitors. Clin Cornerstone 2005; 7: 47-56.
29. Padma-Nathan H. Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction. Am J Cardiol 2003; 92 (9A): 19M-25M.
30. Zhang X, Feng Q, Cote RH. Efficacy and Selectivity of Phosphodiesterase-Targeted Drugs in Inhibiting Photoreceptor Phosphodiesterase (PDE6) in Retinal Photoreceptors. Invest Ophthalmol Vis Sci 2005; 46: 3060-6.
31. Cunningham AV, Smith KH. Anterior ischemic optic neuropathy associated with Viagra. J Neuroophthalmol 2001; 21: 22-5.
32. Escaravage GK, Wright JD, Givre SJ. Tadalafil associated with anterior ischemic, optic neuropathy. Arch Ophthalmol 2005; 123: 399-400.
33. Laties AM, Zrenner E. Viagra (sildenafil citrate) and ophthalmology. Prog Ret Eye Res 2002; 21: 485-506.
34. Pomeranz HD, Smith KH, Hart WM, Egan RA. Sildenafil-associated nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2002; 109: 584-7.
35. The Ischemic Optic Neuropathy Decompression Trial Research Group. Characteristics of patients with nonarteritic anterior ischemic optic neuropathy eligible for the Ischemic Optic Neuropathy Decompression Trial. Arch Ophthalmol 1996; 114: 1366-74.
36. Rucker JC, Biousse V, Newman NJ. Ischemic optic neuropathies. Curr Opin Neurol 2004; 17: 27-35.
37. Feldman HA, Johannes CB, Derby CA, et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Prev Med 2000; 30: 328-38.
38. Roumeguere T, Wespes E, Carpentier Y,et al. Erectile dysfunction is associated with a high prevalence of hyperlipidemia and coronary heart disease risk. Eur Urol 2003; 44: 355-69.
39. Gorkin L, Hvidsten K, Sobel RE, Siegel R. Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy. Int J Clin Pract 2006; 60(4): 500-3.
40. Weeks II JL, Zoragbi R, Beasley A, Sekhar KR, Francis SH, Corbio JD. High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients. Int J Impot Res 2005; 17: 5-9.
41. Seftel AD, Farber J, Fletcher J, et al. A three-part study to investigate the incidence and potential etiologies of tadalafil-associated back pain or myalgia. Int J Impot Res 2005; 17 (5): 455-61.
42. McMahon C. Efficacy and safety daily tadalafil in men with erectile dysfunction previously unresponsive to on demand tadalafil. J Sex Mod 2004; 1: 292-300.
43. McMahon C. Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med 2005; 2: 415-24.
44. Hanson-Divers C, Jackson SE, Lue TF, Crawford SY, Rosen RC. Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol 1998; 159: 1541-7.
45. Buvat J, Van Ahlen H, Schmitt H, Chan M, Kuepfer C, Varanese L. Efficacy and safety of two dosing regimens of tadalafil and patterns of sexual auttivity in men with diabetes mellitus and erectile dysfunction: scheduled use vs. on-demand regimen evaluation (SURE) study in 14 European countries. J Sex Med 2006; 3: 512-520.
46. Moncada I, Damber JE, Mirone V, et al. Sexual intercourse attempt patterns with two dosing regimens of tadalafil in men with erectile dysfunction: Resuits from the SURE study in 14 European countries. J Sex Med 2005; 2: 668-74.
47. Mirone V, Costa P, Damber JE, et al. Ad evaluation of an alternative dosing regimen with tadalafil 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries. Eur Urol 2005; 47: 846-54.
48. Sáenz de Tejada I, Anglin G, Knight JR, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002; 25: 2159-2164.
49. Porst H, Giuliano F, Glina S, et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: Results of a multicenter, randomized, double-blind, placebo-controled trial. Eur Urol 2006; 50(2): 351-9.
50. Hatzichristou D, Gamba M, Rubio-Aurioles E, et al. Tadalafil once-a-day is efficacious in men with diabetes mellitus and erectile dysfunction. Submitted: Diabetic Medicine.
51. Kloner RA, Jackson G, Hutter AM, et al. Cardiovascular safety update of tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing. Am J Cardiol 2006; 97: 1778-1784.
52. Aversa A, Greco E, Bruzziches R, Pili M, Rosano GM, Spera G. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res 2007; 19(2): 200-7.
53. Proietti M, Aversa A, Letizia C, et al. Erectile dysfunction in systemic sclerosis: effects of longterm inhibition of phosphodiesterase type-5 on erectile function and plasma endothelin-1 levels. J Rheumatol 2007; 34(8): 1712-1717.
54. Ann GJ, Sohn YS, Kang KK, et al. The effect of PDE5 inhibition on the erectile function in streptozotocin-induced diabetic rats. Int J Impot Res 2005; 17: 134-141.
55. Foresta C, Ferlin A, De Toni L, et al. Circulating endothelial progenitor cells and endothelial function after chronic Tadalafil treatment in subjects with erectile dysfunction. Int J Impot Res 2006; 18: 484-488.
56. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005; 294: 2996-3002.
57. Jackson G, Kloner RA, Costigan TM, Warner MR, Emmick JT. Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events. J Sex Med 2004; 1(2): 161-7.
58. Kahirsagar A, Seftel A, Ross L, Mohamed. M, Niederberger C. Predicting hypogonadism in men based upon age, presence of erectile dysfunction, and depression. Int J Impot Res 2006; 18: 47-51.
59. Kalyani RR, Dobs AS. Androgen deficiency, diabetes, and the metabolic syndrome in men. Curr Opin Endocrinot Diabetes Obes 2007; 14(3): 226-34.
60. Nieschlag E, Behre E, Bouchard HM, et al. Testosterone replacement therapy: current trends and future directions. Hum Reprod Update 2004; 10 (5): 409-419.
61. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006; 154 (6): 899-90.
62. Aversa A, Bruzziches R, Spera G. A. rationale for the use of testosterone salvage in treatment of men with erectile dysfunction failing phosphodiesterase inhibitors. Endocrinologist 2005; 15 (2): 99-105.
63. Morelli A, Filippi S, Mancina R, et al. Androgens regulate phosphodiesterase Type 5 expression and functional activity in corpora cavernosa. Endocrinology 2004; 145 (5): 2253-63.
64. Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 2003; 58: 632-8.
65. Kalinchenko SY, Kozlov GI, Gontcharov NP, Katsiya GV. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 2003; 6(2): 94-9.
66. Jannini EA, Screponi E, Carosa E, et al. Lack of sexual activity from erectile dysfunction is associated with a reversible reduction in serum testosterone. Int J Androl 1999; 22(6): 385-92.
67. Carosa E, Martini P, Brandetti F, et al. Type V phosphodiesterase inhibitor treatments for erectile dysfunction increase testosterone levels. Clin Endocrinol (Oxf) 2004; 61(3): 382-6.
68. Greco EA, Pili M, Bruzziches R, Corona G, Spera G, Aversa A. Testosterone:estradiol ratio changes associated with long-term tadalafil administration: a pilot study. J Sex Med 2006; 3(4): 716-22.
69. Gazzaruso C, Giordanetti S, De Amici E, et al. Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation 2004; 110(1): 22-6.